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Abstract 
 
Chromium Chloride Increases Insulin-Stimulated Glucose Uptake In The Perfused 
Rat Hindlimb 
 
 
 
 
Phillip Gene Doerner III, M.S. Kin. 
The University of Texas at Austin, 2010 
 
Supervisor:  John L. Ivy 
 
Chromium has been reported to increase glucose clearance in insulin resistant and 
diabetic populations.  Skeletal muscle is the tissue primarily responsible for glucose 
clearance.  We therefore tested the effect of chromium chloride (CrCl3) on skeletal 
muscle glucose uptake both in the absence and presence of a submaximal level of insulin 
via the rat hindlimb perfusion technique. 0.096 µM CrCl3 was used with and without 200 
µU/ml insulin.  Our testing showed that insulin significantly increased [H3]-2 
deoxyglucose (2-DG) uptake in both the gastrocnemius and quadriceps muscles.  
Additionally, the combination of CrCl3 and insulin (Cr-sIns) led to greater amounts of 2-
DG uptake than insulin alone (sIns) in both the gastrocnemius (Cr-sIns 6.49±0.75 
µmol/g/h, sIns 4.83±0.42 µmol/g/h) and quadriceps (Cr-sIns 6.74±0.62 µmol/g/h, sIns 
4.54±0.43 µmol/g/h).  However, CrCl3 without insulin (Cr) had no affect on 2-DG uptake 
above basal (Bas) in both the gastrocnemius (Cr 1.45±0.14 µmol/g/h, Bas 1.61±30 
µmol/g/h) and the quadriceps (Cr 1.35±0.15 µmol/g/h, Bas 1.27±0.13 µmol/g/h).  It has 
been speculated that chromium works to increase glucose uptake by increasing insulin 
 vi 
signaling. To examine this, we used western blotting analysis to test both Akt and AS160 
phosphorylation in the mixed gastrocnemius. We found that insulin increased Akt and 
AS160 phosphorylation, but chromium had no affect on Akt (Cr-sIns 25%±2%, sIns 
22%±4%) or AS160 (Cr-sIns 35%±5%, sIns 36%±4%) phosphorylation in the absence or 
presence of insulin. Our results suggest that supplementation with CrCl3 can lead to an 
increase in glucose uptake in skeletal muscle, but only in the presence of insulin.  
However, this effect of CrCl3 does not appear to be a result of enhanced insulin signaling. 
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Introduction 
Diabetes mellitus is one of the largest concerns currently facing human health.  
There are two forms of diabetes, type 1 and type 2.  While type 1 diabetes is 
characterized by an autoimmune attack on the insulin producing β-cells of the pancreas, 
type 2 diabetes is the result of lifestyle choices and cases of type 2 diabetes are on the rise 
(75).  Obesity, as a result of diet and inactivity, has long been thought to lead to type 2 
diabetes (4, 15).  Insulin resistance characterizes type 2 diabetes, resulting in impaired 
glucose tolerance.  More specifically, type 2 diabetes results in the peripheral muscles’ 
inability to react to released insulin and disposal of blood glucose (23). 
 Insulin activates glucose transport into skeletal muscle by eliciting the 
translocation of GLUT4 from intracellular areas to the plasma membrane.  Two of the 
most important signaling proteins involved in this process are Akt and AS160.  Akt, also 
known as PKB, is an insulin controlled protein kinase that is involved in multiple 
processes in the body (42).  AS160 is a 160 kDa substrate of Akt and is one of the final 
signaling proteins involved in GLUT4 translocation (21).  In the basal state, AS160 acts 
as a brake on a Rab-GDP protein that is thought to control GLUT4 translocation.  Once 
AS160 is phosphorylated, the Rab-GDP protein is allowed to become active as a Rab-
GTP, allowing GLUT4 to translocate to the plasma membrane (58, 62). 
 Multiple treatment methods have been put into practice to combat type 2 diabetes.  
In some cases, simple augmentation of diet and exercise has shown to be successful in 
treating type 2 diabetes (1, 17).  For some patients, medication such as Metformin and 
Sulfonylurea have been shown to be successful in treating the symptoms of type 2 
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diabetes (33, 64).  One method that has been proposed as a combatant for type 2 diabetes 
is supplementation with chromium (52, 57).   
 Chromium, while fairly unstudied, has been known about for some time.  
Chromium was first mentioned as possibly being involved with glucose uptake in 1959 
(59), and since then has generated some controversy.  While many researchers believe 
that chromium is necessary for human glucose control, others doubt its efficacy (66).  
Still, chromium has been deemed an essential nutrient needed in human nutrition and 
used as a supplement to increase lean weight in farm animals as well as being one of the 
highest sold supplements for humans (2, 49). 
 One of the earliest studies showing the necessity of chromium in humans involved 
a patient who was receiving total parenteral nutrition (38).  The patient began showing 
signs of insulin resistance, needing large amounts of insulin to dispose of glucose.  After 
increasing the amount of insulin given and seeing no improvements, chromium was 
added, reversing the effects of the insulin resistance and allowing for a decrease in the 
amount of insulin provided.  Additionally, multiple studies in populations of patients with 
insulin resistance have shown that chromium supplementation leads to improved glucose 
tolerance (7, 12, 65).  However, additional studies have shown that chromium 
supplementation has no effect on glucose uptake in patients with normal glucose 
tolerance (5, 70).  It has been demonstrated that the absorption rate of chromium is 
extremely low (10, 47).  This low rate of absorption from the gut and into the muscles 
may in part lead to some of the discrepancies seen in studies investigating chromium.    
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 While it has been shown repeatedly that chromium ingestion in diabetic 
populations results in improved glucose metabolism, the mechanism by which chromium 
affects glucose disposal is unknown.  Much of the research into how chromium augments 
glucose metabolism has been completed recently, and is still inconclusive.  The majority 
of studies have shown that chromium increases insulin signaling by increasing 
phosphorylation of the insulin receptor, leading to an increase in Akt activation (27, 67, 
68).  However, other studies have determined that augmentation of the plasma membrane 
is responsible for the increase in glucose uptake (22, 50). 
 The purpose of this study was to investigate the effects of chromium 
supplementation on skeletal muscle glucose uptake in the presence and absence of a 
submaximally-stimulating concentration of insulin.  By performing perfusions with and 
without insulin, we were able to determine if chromium directly affects glucose uptake, 
or simply augments insulin action. 
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Methods 
Animals.  All research and handling procedures were approved by the Institutional 
Animal Care and Use Committee (IACUC) of The University of Texas at Austin. 
Twenty-eight male Sprague Dawley rats (Harlan, Houston, TX) were obtained for testing.  
Rats were received at 7 weeks of age.  The rats were housed 2 to a cage and fed a 
standard laboratory chow (ProLab RMH 1800, Labdiet, Brentwood, MO) and provided 
with water ad libitum.  The room housing the animals was kept at 210 C with an artificial 
12 hour/12 hour light-dark cycle.  Upon arrival, rats were randomly separated by weight 
into 1 of 4 groups: chromium with sub maximal insulin (Cr-sIns, n=8), sub maximal 
insulin (sIns, n=9), chromium without insulin (Cr, n=6), and basal (Bas, n=5).  
 
Experimental Design and Surgery. In order to determine glucose uptake in the rat 
skeletal muscle, the hindlimb perfusion technique was utilized.  Hindlimb perfusion has 
been shown to be both a viable and popular experimental model to examine glucose 
metabolism under physiological conditions (18, 71). 
Rats were subjected to testing at 9 weeks of age.  After a 12-hour fast, rats were 
anesthetized with an intraperitoneal injection of pentobarbital sodium (6.5 mg/100 g body 
weight).  The surgical technique and the perfusion apparatus were similar to that 
previously described (37, 56).  Briefly, the purpose of the surgery was to tie off vessels in 
the abdominal cavity and the left limb while exposing the inferior vena cava and 
descending aorta.  Cannulation of the right iliac artery and inferior vena cava could be 
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performed, thus allowing the perfusate to flow from the arterial catheter, to the 
circulatory bed of the right hindlimb, and finally out through the venous catheter. 
 
Perfusate solutions. All solutions for the perfusion procedure were prepared in 6% BSA.  
2 mM Na-pyruvate was added to the 6% BSA for the basal washout solution.  The Bas 
perfusate solution contained 2 mM Na-pyruvate, 6 mM glucose, 2 mM mannitol, 0.2 
µCi/ml H3-2 deoxyglucose and 0.15 µCi/ml C14-Sucrose.  The washout solution for the 
Cr group contained 2 mM Na-pyruvate and 0.096 µM CrCl3.  The Cr perfusate solution 
was composed of 2 mM Na-pyruvate, 0.096 µM CrCl3, 6 mM glucose, 2 mM mannitol, 
0.2 µCi/ml H3-2 deoxyglucose and 0.15 µCi/ml C14-Sucrose.  The washout solution for 
the sIns group was made of 2 mM Na-pyruvate and 200 µU/ml insulin.  The perfusate 
solution contained 2mM Na-pyruvate, 200 µU/ml insulin, 6 mM glucose, 2 mM 
mannitol, 0.2 µCi/ml H3-2 deoxyglucose and 0.15 µCi/ml C14-Sucrose.  The Cr-sIns 
washout solution was made of 2 mM Na-pyruvate, 200 µU/ml insulin and 0.096 µM 
CrCl3.  The perfusate solution for the Cr-sIns group contained 2mM Na-pyruvate, 200 
µU/ml insulin, 0.096 µM CrCl3, 6 mM glucose, 2 mM mannitol, 0.2 µCi/ml H3-2 
deoxyglucose and 0.15 µCi/ml C14-Sucrose. 
  
Hindlimb perfusion The cannulated rat was placed in line with the perfusion system.  
The perfusate was continuously mixed on a magnetic stir plate.  The perfusate first 
passed through a roller pump, which was calibrated at 6 ml/min for the washout and 3 
ml/min for the perfusate.  The perfusate then passed through approximately 3 meters of 
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Silastic tubing (Dow Corning, Midland, MI) contained in an artificial lung, which was 
gassed with a mixture of 95% O2 and 5% CO2.  Next, the perfusate passed through a 
heated water jacket maintained at 370 C, and then through a bubble trap before entering 
the hindlimb of the rat via the arterial catheter.  After circulating through the right 
hindlimb the perfusate exited through the venous catheter and was collected in a beaker 
on ice for later analysis. 
 The hindlimb was allowed to stabilize during a 10 minute washout period.  After 
the washout period, the rat was perfused for 25 minutes with the nonrecirculating 
perfusate solution.  Aliquots of the arterial samples were taken in order to determine the 
specific activity of the isotopes to help determine the skeletal muscle glucose uptake. 
After the perfusion was performed, the right gastrocnemius and quadriceps were 
removed, freeze clamped in liquid nitrogen and stored at -800 C for later analysis. 
 
Skeletal muscle glucose uptake. Pieces of frozen gastrocnemius and quadriceps were cut 
and weighed.  The pieces were digested in 1ml of 1M KOH for 20 minutes at 60OC. The 
digested muscle was neutralized with 1ml of 1M HCL before 300 µl of the mixture was 
added to 6 ml BioSafe II scintillation cocktail (Research Products International, Mt. 
Prospect, IL).  An LS-6500 Multi Purpose Scintillation Counter (Beckman Coulter, Inc., 
Brea CA) was used to count duplicate samples of 3H and 14C.  Uptake of 2-DG in the 
muscle was calculated as the difference between total muscle 2-DG and extracellular 2-
DG.  Extracellular space was determined from the from tissue concentration of [14C]-
Sucrose, since the sucrose cannot cross the plasma membrane (34-36). 
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Tissue processing for signaling protein immunoblotting. Frozen gastrocnemious muscle 
was pulverized in a mortar and pestle in liquid nitrogen.  Homogenization buffer (20mM 
Hepes, 2 mM EGTA, 50 mM NaF, 100 mM KCl, 0.2 mM EDTA, 50 mM 
glycerophosphate, 1 mM DTT, 0.1 mM PMSF, 1 mM Benzamidine, 0.5 mM Na 
Vanadate) was added to the chilled mortar.  After pulverization, the powdered muscle 
was added to a glass tissue grinder (Corning Stirrer Type RZR1, Wiarton, Ont. Canada) 
with additional homogenization buffer to dilute the sample at a dilution factor of 9:1.  
The samples were thoroughly mixed in the grinder for 10 seconds 3 times each.  The 
homogenate was then centrifuged at 40C for 10 minutes at 14,000 x g.  Following the 
centrifugation, the protein concentration of the supernatant was analyzed using the 
Bradford method (19) (Bio-Rad Laboratories, Hercules, CA).  The supernatant was then 
aliquoted into multiple vials and stored at -80 0C until analyzed.   
 
Antibodies for signaling protein immunoblotting. The antibodies used were specific for 
the proteins examined; phosphorylated AS160 (Thr642 #4288S), phosphorylated 
Akt(Thr308, #4056S), total AS160 (Anti-AS160 Rab-GAP Rabbit antiserum) and total 
Akt (Akt Rabbit Ab). A horseradish peroxidase (HRP)-conjugated secondary anti-rabbit 
IgG was used for a secondary antibody. All antibodies were purchased from Cell 
Signaling Technology (Danvers, MA) except total AS160, which was purchased from 
Upstate (Temecula, CA). 
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Signaling protein immunoblotting. Equal amounts of muscle protein (40 µg) were 
separated by SDS-PAGE using 10% polyacrylamide gels and then transferred on to a 
nitrocellulose membrane (Millipore Corp, Bedford, MA) using a wet transfer unit (Bio-
Rad Laboratories, Hercules, CA).  The membranes were blocked before being incubated 
overnight with primary antibody.  The following day the membranes were incubated for 
90 minutes with secondary antibodies and then visualized with enhanced chemi-
luminescence (ECL, Perkin Elmer, Boston, MA). After exposure of phosphorylated 
proteins, membranes were placed in a stripping buffer (pH 6.7, 7.5g Tris Base, 20g SDS, 
7 ml β-me) for one hour.  Membranes were then washed 2 times for 5 minutes and then 
probed for total protein. Protein blots were quantified by a ChmDoc ECL detection 
system and Quantitiy One software (both Bio-Rad, Hercules, CA).  Akt and AS160 
phosphorylation was analyzed as a percentage of total Akt and AS160. 
  
Statistics. Data from the glucose uptake and protein phosphorylation was subjected to a 
two-way analysis of variance (two-way ANOVA) with chromium and insulin being the 
two independent variables, and upon verification of significant interaction, means were 
compared using Fisher’s Least Significance Difference post hoc test.  A level of P<0.05 
was deemed statistically significant.  All values are expressed as means ± SEM. 
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Results 
Animal characteristics. 28 male Sprague Dawley rats were used in this study.  Rats were 
aged 9 weeks before undergoing testing and were randomized by weight into separate 
groups (Cr-sIns 295.89±5 g, sIns 296.38±3 g, Cr 291±5 g, Bas 296±3 g). 
Chromium increases glucose uptake in insulin-stimulated skeletal muscle. Glucose 
uptake for the gastrocnemius is shown in Fig. 1, and for the quadriceps is shown in Fig. 
2.  Insulin had a significant effect on skeletal glucose uptake in both the gastrocnemius 
and quadriceps, leading to a 3.77 and a 4.26 fold increase, respectively. Chromium alone 
had no affect.  However, there was significant interaction between chromium and insulin.  
Post hoc analysis indicated the chromium and insulin together increased glucose uptake 
compared to insulin alone in the gastrocnemius by 42% (Cr-sIns 6.86±0.74 µmol/g/h, 
sIns 4.83±0.42 µmol/g/h) and in the quadriceps by 47% (Cr-sIns 6.67±0.70 µmol/g/h, 
sIns 4.54±0.43 µmol/g/h). When chromium was perfused in the absence of insulin it had 
no effect on skeletal muscle glucose uptake. 
Chromium has no affect on Akt phosphorylation. Phosphorylation of Akt at Thr308 in 
the gastrocnemius was analyzed using Western blots.  Results are shown as a percentage 
of the total Akt protein content.  Insulin perfusion resulted in an increase in Akt 
phosphorylation, while chromium had no affect on Akt phosphorylation in the absence of 
insulin (Cr 4%±1%, Bas 4%±1%) or in the presence of insulin (Cr-sIns 23%±2%, sIns 
22%±4%).   
Chromium has no affect on AS160 phosphorylation. Phosphorylation of AS160 at 
Thr642 in the gastrocnemius was analyzed using Western blots.  Results are shown as a 
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percentage of the total protein content.  Insulin perfusion led to a 2.71 fold increase in 
AS160 phosphorylation.  Chromium supplementation had no affect on AS160 
phosphorylation in the absence of insulin (Cr 14%±3%, Bas 12%±3%) or in the presence 
of insulin (Cr-sIns 37%±5%, sIns 36%±4%). 
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FIGURES 
 
Figure 1. The effect of chromium on glucose uptake in the gastrocnemuis with and 
without submaximal insulin. The right hindlimb was prepared for hindlimb perfusion 
and washed-out for 10 minutes, followed by 25 minutes of perfusion with a perfusate 
containing neither chromium nor insulin (Bas), chromium with no insulin (Cr), 
submaximal insulin without chromium (sIns) or chromium with submaximal insulin (Cr-
sIns).  Values are means ± SEM in µmol/g/h. Means with difference letters are 
significantly different from each other (P<0.05). 
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Figure 2. The effect of chromium on glucose uptake in the quadriceps with and 
without submaximal insulin. The right hindlimb was prepared for hindlimb perfusion 
and washed-out for 10 minutes, followed by 25 minutes of perfusion with a perfusate 
containing neither chromium nor insulin (Bas), chromium with no insulin (Cr), 
submaximal insulin without chromium (sIns) or chromium with submaximal insulin (Cr-
sIns).  Values are means ± SEM in µmol/g/h. Means with difference letters are 
significantly different from each other (P<0.05). 
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Figure 3. The effect of chromium on Akt Thr308 phosphorylation with and without 
submaximal insulin.  Data are expressed as a fraction of total Akt content. The right 
hindlimb was prepared for hindlimb perfusion and washed-out for 10 minutes, followed 
by 25 minutes of perfusion with a perfusate containing neither chromium nor insulin 
(Bas), chromium with no insulin (Cr), submaximal insulin without chromium (sIns) or 
chromium with submaximal insulin (Cr-sIns).  Values are means ± SEM.  Means with 
difference letters are significantly different from each other (P<0.05). 
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 Figure 4. The effect of chromium on AS160 Thr642 phosphorylation with and 
without submaximal insulin.  Data are expressed as a fraction of total As160 content. 
The right hindlimb was prepared for hindlimb perfusion and washed-out for 10 minutes, 
followed by 25 minutes of perfusion with a perfusate containing neither chromium nor 
insulin (Bas), chromium with no insulin (Cr), submaximal insulin without chromium 
(sIns) or chromium with submaximal insulin (Cr-sIns).  Values are means ± SEM.  
Means with difference letters are significantly different from each other (P<0.05). 
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Discussion 
The present study has two key findings.  First, it was shown that perfusion with 
chromium chloride can lead to an increase in insulin-stimulated glucose uptake in normal 
skeletal muscle.  In the presence of a submaximally stimulating insulin concentration, 
chromium increased glucose uptake in the gastrocnemius and quadriceps muscles by 42% 
and 47%, respectively.  Additionally, it was shown that chromium perfusion only worked 
in the presence of insulin.  This suggests that chromium works as a cofactor of insulin, 
enhancing its action. 
Many studies have shown that chromium supplementation increases glucose 
metabolism in insulin resistant populations (16, 38, 51).  However, when healthy subjects 
have been examined, it has been shown that chromium has no effect on glucose 
metabolism (14, 70).  A meta-analysis performed by Althuis et al. (5) examined the 
effects of chromium supplementation on glucose response.  The authors determined that 
chromium supplementation had no effect on glucose response in non-diabetic subjects.  A 
definite explanation as to why chromium seems ineffective in healthy populations has yet 
to be determined. 
Studies in both humans (10, 39) and animals (41, 46) have shown that chromium 
absorption is very low.  Specifically, Oberleas et al. (47) investigated the transit time of 
chromium through the gut in rats. The study showed that the transit time of chromium is 
short, leading to lower levels of uptake in the gut.  With chromium absorption in the gut 
being low, chromium levels in the blood will in turn be low (8, 41).  These results suggest 
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that chromium levels in the blood, thus the amounts of chromium transported to the 
muscle, are very low.  Additionally, a study by Anderson and Kozlovsky (10) as well as a 
study by Offenbacher et al. (48) analyzed chromium absorption in humans.  Anderson 
and Kozlovsky (10) found that in subjects consuming 10 µg of chromium, 2% was 
absorbed, while in subjects consuming 40 µg of chromium, only 0.5% was absorbed.  
Offenbacher et al. (48) found that in two subjects, daily chromium intake was 36.9 and 
36.7 µg of chromium a day and absorption was only 0.9 and 0.5 µg of chromium, 
respectively.   
Taking these studies together, it can be inferred that while necessary, the amount 
of chromium needed in the body is very low.  As a result of low absorption in the gut, 
only small amounts of chromium reach the muscles.  By utilizing the hindlimb perfusion 
technique, the gut was bypassed and the muscle was exposed to high levels of chromium.  
The result of this high level of exposure led to increased insulin-stimulated skeletal 
muscle glucose uptake.  Oral supplementation does not seem to present a problem in a 
diabetic population.  Even though chromium absorption is low, apparently very little is 
needed to increase glucose uptake in otherwise unhealthy and impaired muscles.  
However, blood chromium levels needed to increase glucose uptake in insulin resistant 
muscle appears to be inadequate to positively influence non-insulin resistant muscle.  
Still, it is possible that the exposure of healthy muscle to high levels of chromium could 
have a similar effect as to that seen in insulin resistant muscle. 
In addition to glucose uptake, the effect of the perfusion of chromium on insulin 
signaling was analyzed in this study.  The majority of studies have suggested that 
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chromium increases glucose uptake by augmenting the insulin-signaling pathway via 
increasing activity of the insulin receptor kinase (7, 25, 68).  This in turn would lead to an 
increase in downstream signaling, such as increased Akt phosphorylation.  Yang et al. 
(72) analyzed chromium and Akt phosphorylation in mouse 3T3-L1 adipocytes.  The 
authors found that the addition of chromium to insulin-stimulated cell cultures resulted in 
Akt phosphorylation above that of insulin alone.  Additionally, Dong et al. (27) showed 
chromium increases Akt phosphorylation in chronically supplemented mice. Insulin 
resistant mice underwent 9 weeks of supplementation with Cr(D-phe)3.  When chromium 
supplemented mice were given an intraperitoneal injection of insulin, Akt 
phosphorylation levels of insulin resistant mice equaled that of healthy control mice.  Our 
results showed chromium had no effect on either insulin-stimulated or noninsulin-
stimulated Akt phosphorylation. We also found that chromium had no affect on AS160 
phosphorylation under these conditions.  This would be expected, as we saw no increase 
in Akt phosphorylation in the presence or absence of insulin. 
Since we found in the present study that glucose uptake increased without an 
increase in insulin signaling, there must be some other mechanism responsible.  It has 
been reported that chromium supplementation affects glucose uptake through 
augmentation of the fluidity of the plasma membrane (22, 29, 50).  It is postulated that 
GLUT4 has an increased affinity for areas of the plasma membrane that exhibit greater 
fluidity, leading to an increased incorporation of GLUT4 into the plasma membrane (53).   
Pattar et al. (50) found that chromium increased membrane fluidity in mouse 3T3-L1 
adipocytes. Evans and Bowman (29) found that the addition of chromium led to an 
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increase in plasma membrane fluidity in rat myoblasts.  Additionally, the authors found 
that the increase in plasma membrane fluidity led to an increase in glucose uptake.  Chen 
et al. (22) examined the effect chromium had on both membrane fluidity and glucose 
uptake in 3T3-L1 adipocytes cultured in a high glucose medium.  The results suggested 
that chromium increased membrane fluidity and insulin-stimulated glucose uptake.  
Membrane fluidity was not analyzed in our study.  However, as we saw an increase in 
glucose uptake without alteration of the insulin-signaling pathway, this could be a viable 
explanation as to the mechanism of action of chromium. 
It has been shown that chromium does not act alone but only in the presence of 
insulin (22, 51).  This has been confirmed in the present study.  Chen et al. (22) showed 
that chromium supplementation led to greater insulin-stimulated glucose uptake in 3T3-
L1 adipocytes without an increase in insulin signaling.  Their results indicated that there 
was an increase in the amount of GLUT4 near the plasma membrane in the basal state 
when chromium was present.  However, glucose uptake was not increased unless insulin 
was added.  The authors stated that since there was more GLUT4 near the plasma 
membrane, once insulin was added greater amounts of GLUT4 could be incorporated into 
the plasma membrane, leading to greater glucose uptake.  This could explain the results 
seen in our study.  A combination of more GLUT4 near the plasma membrane, and more 
fluidity in the plasma membrane, could result in an increase in plasma GLUT4 and 
glucose uptake without an alteration in insulin signaling.   
Chromium has been shown to increase insulin signaling in insulin resistant 
muscles (7, 68, 72).  However, when non-insulin resistant muscles or adipose cultures 
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were examined, there was no alteration in insulin signaling, but an increase in plasma 
membrane fluidity (22, 29, 50).  There is a possibility that both of these are viable 
mechanisms of chromium action.  In insulin resistant muscles, in which the insulin signal 
is blunted, chromium may enhance insulin signaling to that of non-insulin resistant 
skeletal muscle.  In non-insulin resistant muscle, the insulin signal is sufficient for 
adequate skeletal muscle glucose uptake.  By altering plasma membrane fluidity, more 
GLUT4 can be incorporated into the plasma membrane, resulting in increased skeletal 
muscle glucose uptake.   
 In conclusion, we have determined that it is possible to increase insulin-stimulated 
glucose uptake with chromium supplementation in otherwise healthy skeletal muscle.  
Unfortunately, we were unable to determine how chromium increased glucose uptake 
under these conditions.  As the mechanism of action of chromium has not yet been 
determined, future research should continue to examine how chromium supplementation 
increases glucose uptake.   
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Background Literature 
Chromium is an essential trace mineral with an atomic number of 51.  While this 
element can occur in many oxidation states, ranging from -2 to +6, it is most commonly 
found in the trivalent oxidation state, since this is most stable (3, 43).  Research into the 
necessity of chromium and its influence in the body began in Germany in 1959 (44).  
Chromium is commercially available in many different forms.  Chromium chloride 
(CrCl3) and chromium picolinate (CrPic) are the most common found. 
 The main utilization for chromium has been for bettering glucose sensitivity.  The 
results of studies analyzing the benefit of chromium supplementation in both humans and 
animals on glucose tolerance have been mixed.  Chromium has also been investigated for 
control and digestion of lipids, lowering of blood pressure (54) as well as increasing lean 
body mass in farm animals (49). 
 Overall, the efficacy of chromium supplementation in humans regarding glucose 
disposal has been disputed.  Although there are numerous studies exemplifying the 
benefits of chromium on certain populations, many others refute this.  The evidence 
suggests chromium may only be effective in certain populations, namely diabetics and 
those with nutritional deficiencies.  Chromium supplementation is thought to assist those 
with poor insulin signaling by increasing insulin’s actions at different points along the 
insulin-signaling pathway, although the specific mechanism has not yet been determined.   
CHROMIUM ABSORPTION 
One of the greatest difficulties when dealing with chromium supplementation is 
the absorption of chromium.  MacKenzie et al. (41) analyzed radioactively labeled 
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chromium compounds supplemented straight into the intestines, avoiding the initial steps 
of digestion.  It was found that chromium (VI) was absorbed more efficiently and the 
blood concentration of chromium (VI) was significantly higher than the concentration of 
chromium (III).  However, when chromium is supplemented orally, there is little 
difference in the valence activity of the element.  Some researchers suggest that 
chromium (VI) is reduced to chromium (III) when ingested orally (26, 51).  In humans 
(39), five subjects were given a liter of drinking water with different levels of chromium 
(VI) (0.1, 0.5, 1.0, 5.0, and 10.0 mg per liter) added.  The subjects ingested 1 liter of 
supplemented water a day, starting with the lowest concentration for three consecutive 
days before increasing the dosage.  Observing the overall chromium concentration in 
both the plasma and red blood cells, the fluctuations occur similarly to ingestion of 
chromium (III).  Earlier animal work has shown that when chromium (VI) is given 
intravenously or intratracheally, the plasma concentration levels drop at an accelerated 
rate compared to the red blood cell chromium concentrations(28, 32, 69).  However, in 
this study (39), after cessation of supplementation, there was a very rapid decrease in the 
red blood cell chromium concentration, similar to the decrease seen in plasma chromium 
concentration.  Coogan et al. (24) demonstrated the differences in chromium kinetics in 
the red blood cells.  This study showed that radioactively labeled chromium (VI) 
administered intravenously resulted in high concentrations in the blood while intravenous 
chromium (III) resulted in low levels of blood chromium that decreased rapidly after 
treatment.  Additionally, orally administered chromium (VI) resulted in low levels of red 
blood cell chromium concentration that again decreased after administration.  Therefore, 
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it can be concluded that there are different kinetics for chromium depending on the 
method of administration.  Regardless if this is due to the reduction of chromium (VI) to 
chromium (III) or some other phenomenon, it can be determined that while chromium 
(VI) shows efficient uptake when given directly in the blood compared with chromium 
(III), this advantage is negated when supplementation is done orally. 
 Anderson and Kozlovsky (10) examined subjects and their meals. The chromium 
levels in the food were analyzed, as well as urinary excretion of chromium and chromium 
absorption.  The majority of subjects consumed levels of chromium below the daily-
recommended dosage, which is 50 µg a day.  In their study, Anderson and Kozlovsky 
found the mean ingestion of chromium for males was 33 µg a day while women ingested 
an average of 25 µg a day.  The average urinary chromium excretion was 0.19 µg daily, 
and excretion rates were not correlated with ingestion.  The main finding in this study 
was that chromium absorption was inversely proportional to the amount of chromium 
ingested.   The subjects who consumed the highest amounts of chromium had the lowest 
levels of absorption, whereas the subjects who consumed the lowest amounts of 
chromium had the highest levels of absorption.  Subjects who ingested 10 µg of 
chromium had absorption rates of approximately 2%, while those who ingested 40 µg of 
chromium had absorption rates of 0.45%.  When comparing all subjects, females had a 
significantly higher rate of chromium absorption when compared with men (0.93% vs 
0.64%). The difference in chromium absorption between men and women was due in part 
to the men taking in more calories.  This data suggests that while chromium is essential 
for normal human physiological function, the amounts needed are extremely low.  
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Theoretically, if higher ingestion rates result in lower levels of absorption, it would 
suggest that the body is able to tightly control the amount of chromium needed in the 
body. 
 Offenbacher et al. (48) performed a study on two men analyzing their chromium 
intake and excretion.  These men were fed a controlled diet containing constant levels of 
micronutrients, minerals and chromium and were studied during two separate 6-day 
periods.  The level of chromium intake was below the daily-recommended amount, as the 
men had average daily intake levels of 36.9 and 36.7 µg a day.  Of the amount eaten, the 
vast majority of the chromium was excreted in the stool, with a small amount excreted 
through the urine.  Only a very small amount of chromium was absorbed in the body.  
The men had absorption levels of 0.6 and 0.2 µg a day.  This resulted in an average 
absorption rate between the two subjects of approximately 1.8%.  This study is somewhat 
problematic due to the low number of subjects as well as the subjects’ ages, so it may not 
be applicable to a wider population.  However, the data is along the lines of results in 
other studies, so it can be inferred that this is indeed an insightful look at chromium 
absorption. 
A study by Kerger et al. (39) examined the absorption of multiple forms of 
chromium in humans.  Chromium chloride, potassium dichromate with orange juice and 
potassium dichromate where studied for their absorption and excretion rates.  The study 
showed that chromium chloride was the least absorbed (0.13%) and most excreted while 
potassium dichromate was the most readily absorbed (6.9%) and had the lowest rates of 
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excretion.  It should be noted that the chromium was taken in one high dose of 5mg of 
chromium dissolved in deionized water. 
 One reason for the poor absorption rate of chromium may be due to the speed at 
which it passes through the intestines.  Oberleas et al. (47) fed a group of rats 1 gram 
meals containing radioactively labeled chromium chloride.  One hour after the meal, 
animals were sacrificed.  The majority of the chromium was found in the middle sections 
of the small intestines, whereas the majority of the rest of the meal was still located in the 
stomach.  In rats that were sacrificed four hours after ingestion, the majority of the 
chromium had moved out of the small intestines.  A significant amount of the chromium 
was found in the cecum as well as the colon.  The authors speculate that, due to its 
chemical properties, chromium readily bonds with liquids, causing it to be released from 
the stomach and passed through the digestive tract rapidly.  The poor levels of absorption 
seen with chromium are due to the speed with which it travels through the digestive tract 
according to the authors.  While this may explain some reasons why chromium is poorly 
absorbed, it is certainly not the only factor. Other studies have shown that chromium 
absorption is inversely proportional to the amount ingested.  Therefore, while the speed at 
which chromium moves through the digestive system may indeed deter chromium 
absorption, there must be other factors controlling chromium absorption.  
NECESSITY OF CHROMIUM 
Chromium is considered a necessary component of the diet (7).  Multiple studies 
have shown humans and animals with low levels of chromium have impaired glucose 
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uptake and metabolism.  In individuals with low levels of chromium initially, 
supplementing with chromium results in an increase in glucose tolerance. 
 A classic case report published in 1977 was one of the first accounts of the 
necessity of chromium in the diet (38).  A woman who had her intestines removed had to 
rely on intravenous nutrition.  Her daily caloric intake was 1955 kcal/day.  After three 
years of this regiment, the woman’s weight could not be maintained, and her glucose 
tolerance was impaired.  In order to combat the impaired glucose tolerance, 45 units/day 
of insulin was added to her daily infusion.  This was continued for another two years, and 
while glucose tolerance was maintained, she required an increase in calories to maintain 
her weight.  The physicians tested her chromium levels and determined that she was 
chromium deficient.  To improve the patient’s chromium deficiency, 250 μg/day of 
chromium was added to the infusion.  In the absence of exogenous insulin, blood glucose 
levels were decreased from over 200 mg/dL two hours after infusion without chromium 
to less than 120 mg/dL two hours after infusion with chromium.  When insulin was added 
along with chromium, the blood glucose levels were decreased even further.  As the 
chromium treatment continued, the neuropathy seen was reversed, and exogenous insulin 
added to the infusion was no longer needed. 
 In rats, it has been repeatedly shown that chromium deficiency leads to insulin 
resistance (46, 51, 61, 63).  Mertz et al. (46)  raised rats on a chromium deficient diet, 
creating glucose intolerance.  The rats had a glucose removal rate of 1.8%, half of what is 
seen in normal rats.  After receiving an intravenous injection of chromium of varying 
levels, glucose removal was improved to 3.5%.  Chromium was given in doses of 0.1, 
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0.25 and 0.5 µg per 100 g body weight.  The improvement was seen in the higher two 
doses, with no difference between the two treatments.  This suggests that there is a 
plateau effect with chromium supplementation. 
 Striffler and colleagues (60) fed rats a low chromium, high sucrose diet to induce 
glucose intolerance before splitting the rats into a chromium supplemented group and a 
chromium deficient group.  After 24 weeks, rats were subjected to an intravenous glucose 
tolerance test.  Supplemented rats showed a lower area under the curve for their insulin 
response.  The difference attributed to the chromium chloride supplementation was 43%.  
Additionally, the glucose area under the curve was 18% lower in the chromium chloride 
supplemented group.  Glucose clearance rates (KG) were also examined.  It was 
determined that the chromium chloride supplemented group had a KG of 5.29% per 
minute while the chromium deficient group had a KG of 3.58% per minute.  The authors 
stated this led to a 48% more efficient utilization of glucose in the chromium chloride 
supplemented group. 
 Additionally, a second study using a similar protocol was conducted, but was only 
performed for 12 weeks (63).  In this study, rats were fed a basal diet high in sucrose and 
low in chromium to achieve chromium deficiency before the start of the study.  Rats were 
then split into two groups, with one continuing on the chromium deficient diet and the 
other supplemented with 5 ppm chromium chloride in the drinking water.  After 12 
weeks, rats were subjected to an intravenous glucose tolerance test.  While both groups of 
rats showed similar rates of glucose uptake, the group that supplemented with chromium 
chloride had a significantly lower insulin response.  The area under the curve for insulin 
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secretion was two times higher in the deficient diet group compared to the supplemented 
group.  A third group, used as a control, was included in the study and fed normal rat 
chow.  The control group had a similar glucose uptake as the other groups, with the 
insulin area under the curve similar to the chromium chloride supplemented group.  This 
study exemplifies the link between chromium and insulin resistance.  In rats that were 
chromium deficient, more insulin was needed to elicit the same amount of glucose 
uptake.  In rats that underwent chromium supplementation after becoming chromium 
deficient, the negative effects were reversed.  The glucose uptake and insulin response in 
these experimental rats were similar to the control rats.  This shows that chromium is 
necessary for proper glucose uptake and insulin efficiency.   
CHROMIUM AND GLUCOSE INTOLERANCE 
In general, the results of studies on chromium and glucose tolerance have been 
mixed.  A meta analysis by Balk et al. (16) showed that chromium supplementation is 
beneficial in populations with impaired insulin responses and glucose intolerance.  The 
authors also determined that chromium supplementation is not beneficial in persons who 
have normal glucose tolerance.  A meta-analysis by Althuis et al. (5) supports the 
hypothesis that chromium supplementation has no beneficial effects on persons with 
normal glucose tolerance.  However, the authors additionally stated that results from 
studies conducted on subjects with type 2-diabetes are inconclusive.  Of the studies 
investigated, only three analyzing type 2 diabetics met their criteria.  Only one of these 
studies found a difference in glucose uptake or insulin levels during a glucose tolerance 
test (9).  However, Althuis et al. (5) state that this study is not applicable to populations in 
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the western hemisphere.  The study was preformed in China and included subjects of 
very low body weight.  This suggests that the subjects suffered from malnutrition, so the 
positive results may in fact be due to improvements in a chromium deficiency as a result 
of malnutrition. 
 A study by Frauchiger et al. (30) studied subjects who were healthy with normal 
glucose tolerance.  The subjects were fed 75 g of carbohydrate in the form of white bread 
with either a placebo, 400 µg or 800 µg of chromium.  The results showed that while 
there was a significant decrease in capillary blood glucose with chromium 
supplementation, there was no difference when venous glucose levels were examined.  
Additionally, subjects were analyzed individually.  The subjects who had the highest 
glucose area under the curve showed the greatest improvement when chromium was 
supplemented.  These results concur with other studies (13), in that chromium 
supplementation is only beneficial in populations who have impaired glucose tolerance.  
Anderson and colleagues (13) studied 11 females and 6 males.  Subjects were separated 
into a hyperglycemic group and a control group.  The criteria for the hyperglycemic 
group was a glucose concentration between 5.56 and 11.1 mmol/L 90 minutes after an 
oral glucose tolerance test of 1 gram of glucose per kilogram of body weight.  Subjects 
were given either a daily placebo or chromium supplement of 200 µg of chromium 
chloride for four weeks, then given the other treatment for another four week period after 
a one week washout.  The control group showed no difference between treatments while 
the hyperglycemic group showed significant differences.  The glucose levels over 90 
minutes for the control group were 21.2 mmol/L on the placebo treatment and 21.4 
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mmol/L on the chromium treatment.  In the hyperglycemic group, glucose levels after 90 
minutes were 30 mmol/L on the placebo treatment versus 26.5 mmol/L on the chromium 
treatment.  Additionally, insulin levels were the same across treatments in the control 
group while chromium supplementation lowered insulin levels in the hyperglycemic 
group. 
 A second study by Anderson and colleagues (14) examined different populations 
and their reactions to chromium supplementation.  Seventy-six subjects, both male and 
female were supplemented with 200 µg of CrCl3 for three months or a placebo.  This 
study was a cross over study, so each subject received both the placebo and experimental 
treatments.  Two months into the supplementation period and at the end, subjects 
underwent an oral glucose tolerance test.  Fasting glucose and insulin, as well as 90-
minute serum glucose and insulin levels were examined.  When looking at the subjects as 
a whole, there were no significant changes.  However, once the subjects were broken 
down into different groups, differences were seen.  The groups formed were subjects with 
90 minute glucose levels greater than or equal to 100 mg/dl, subjects with 90 minute 
glucose levels less than or equal to fasting and subjects with 90 minute glucose levels less 
than 100 mg/dl, but greater than fasting.  In the group with the highest levels of serum 
glucose, chromium supplementation lead to a decrease in fasting glucose levels from 90 
mg/dl to 84 mg/dl whereas the subjects with glucose levels below 100 mg/dl showed no 
difference in resting glucose levels after three months of supplementation.  Additionally, 
chromium supplementation led to decreases in 90-minute serum glucose levels in 
subjects with the highest glucose levels before supplementation.  90-minute glucose 
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levels were lowered from 135 mg/dl to 115 mg/dl after three months.  The subjects with 
glucose levels between resting and 100 mg/dl showed no difference after 
supplementation.  Additionally, the group with the lowest initial 90-minute glucose levels 
showed an increase in 90-minute glucose levels after three months of chromium 
supplementation.  This is concurrent with a second study by Anderson et al. (11) 
examining subjects with reactive hypoglycemia.  Three months of supplementation with 
200 μg/day of chromium chloride resulted in an increase in serum glucose levels at two 
and four hours after an oral glucose tolerance test.  These results suggest that chromium 
is necessary for proper glucose metabolism, whether subjects suffer from hypoglycemia 
or hyperglycemia.  
 Taken together, research focusing on chromium supplementation and glucose 
intolerance suggests that chromium supplementation helps with glucose metabolism in 
subjects exhibiting insulin resistance.  It has been theorized that chromium increases the 
efficacy of insulin (6, 7, 45).  Therefore, chromium supplementation will not benefit 
those with normal glucose response and insulin action.  Since chromium propagates 
insulin activity, those who must secrete increased levels of insulin to remove glucose 
from the blood stream will benefit from chromium supplementation.  Less insulin will be 
needed to remove blood glucose since insulin action will be increased. 
MECHANISMS 
In general, the majority of studies agree that chromium increases insulin-
stimulated glucose uptake in skeletal muscle.  However, there have been many different 
suggestions as to its mechanisms of action.  Many studies have shown an increase in the 
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insulin-signaling pathway as the mode of action for chromium (6, 44, 46).  There is much 
disagreement on which step in the complicated insulin-signaling cascade is altered.  
However, numerous studies have shown that chromium is ineffective without the 
presence of insulin(22, 55, 72) suggesting that chromium does work in conjunction with 
insulin.  Additionally, it has been suggested that chromium supplementation increases 
membrane fluidity (31, 50), resulting in increased glucose uptake. 
Wang et al. (68) studied insulin resistant cell cultures treated overnight with 
multiple forms of chromium, all of which were in the +3 oxidation state.  Once insulin 
was added, it was shown that chromium increased the tyrosine phosphorylation of the 
insulin receptor through an increase in activity of the insulin receptor tyrosine kinase.  A 
study by Davis and Vincent (25) showed that chromium increases the tyrosine activity 8 
times above that of normal activation.  This study was performed in isolated rat 
adipocytes and additionally showed no chromium effect in the absence of insulin.  In a 
second paper, Vincent proposed a mechanism of how chromium works (67).  According 
to their results, insulin binding to the IR leads to an influx of chromium into the cell.  The 
chromium will then bind to the insulin receptor, resulting in greater activation of the 
tyrosine kinase activity.  As insulin levels drop, chromium is released from the receptor.  
Brautigan et al. (20) showed that pre-treating 3T3-L1 adipocytes with chromium and then 
adding insulin results in an increase of the insulin receptor tyrosine phosphorylation.  
Additionally, vanadate was studied with chromium and insulin.  Vanadate is known to 
increase the tyrosine phosphorylation of the insulin receptor by inhibiting protein tyrosine 
phosphatases (PTP).  PTP dephosphorylates the insulin receptor, decreasing the action of 
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insulin.  When combining insulin, vanadate and chromium, there was no increase in 
insulin receptor tyrosine phosphorylation above that of insulin and vanadate.  It has been 
shown in other studies that chromium supplementation does not affect PTP activity (68).  
Therefore, while chromium does not inhibit insulin receptor dephosphorylation, it does 
increase tyrosine phosphorylation of the insulin receptor in some other manner. 
 Dong et al. (27) compared insulin resistant mice chronically supplemented with 
chromium with control mice.  It was demonstrated that once the mice were stimulated 
with an intrapertional injection of insulin, the supplemented insulin resistant mice showed 
Akt phosphorylation in skeletal muscle on the same level of the control mice.  These 
results were confirmed by Zhao et al (74).  In cultured cardiac cells, it was shown that 
adding chromium and insulin increased Akt Ser473 phosphorylation after 15, 30 and 60 
minutes above that of insulin alone.  Additionally, when Wortmanin was added, 2-deoxy 
glucose uptake was significantly negated.  Wortmanin is an inhibitor of PI-3 Kinase.  PI-
3 Kinase is upstream of Akt in the insulin-stimulated cascade and must be activated in 
order to activated Akt downstream.  This suggests that chromium affects the insulin-
signaling cascade above Akt and not Akt directly.  
In addition to chromium increasing insulin signaling through Akt, Zhao and 
colleagues (74) hypothesized that chromium increases signaling through AMPK.  AMPK 
has been shown to play a role in insulin signaling and GLUT4 translocation (40, 73).  In 
isolated mouse cardiac muscles, the addition of chromium (D-phenylalanine)3 increased 
Thr172 phosphorylation of AMPK.  Additionally, there was an increase of acetyl-CoA 
carboxylase activation, a downstream substrate of AMPK.  It was also shown that 
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glucose uptake increased when adding chromium.  However, the levels of glucose uptake 
were lowered when Compound C, an inhibitor of AMPK, was added in addition to the 
chromium.  These results suggest that chromium supplementation leads to greater glucose 
uptake through AMPK. 
Chen et al. (22) investigated the effect of chromium on insulin-stimulated glucose 
transporter, GLUT4.  The presence of GLUT4 on the plasma membrane was examined in 
3T3-L1 adipocytes.  In cell cultures pretreated with either chromium chloride or 
chromium picolinate, the amount of GLUT4 near the plasma membrane in the basal state 
was increased significantly compared to controls.  Once insulin was added, GLUT4 
translocation to the plasma membrane in the chromium treated cells was above normal.  
The authors concluded that the increase of GLUT4 on the plasma membrane was a result 
of an increase in membrane fluidity.  This conclusion was based on the finding that 
treating 3T3-L1 adipocytes with chromium leads to a loss of cholesterol in the plasma 
membrane, leading to an increase in membrane fluidity.  Other work from the same group 
used similar methods, examining membrane fluidity and insulin-stimulated GLUT4 
translocation (50).  It was found that chromium increased membrane fluidity through loss 
of cholesterol in the plasma membrane, which resulted in an increase in insulin-
stimulated GLUT4 translocation.  Glucose uptake was not examined in the second study. 
 Qiao and colleagues (55) examined chromium supplementation in rat L6 
myoblasts.  Three forms of chromium were investigated, chromium chloride (CrCl), 
chromium picolinate (CrPic) and chromium chelated with small peptides (CrSP).  
Myoblasts were incubated in a medium containing chromium with and without insulin.  
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The incubation lasted for 72 hours.  In addition to investigating glucose uptake, mRNA 
expression levels of IR and GLUT4 were studied.  In the presence of chromium alone, 
there was no increase in glucose uptake.  When adding insulin to chromium 
supplementation, the CrPic and CrSP groups showed greater levels of glucose uptake 
than insulin alone.  While glucose uptake in cells treated with CrCl was not significantly 
higher than cells treated with insulin alone, it was not significantly lower than the other 
two chromium groups.  It was found that chromium supplementation alone led to an 
increase in the mRNA levels of IR, and when insulin was added, this increase was 
amplified.  In cells treated with both chromium and insulin, there was an increase in the 
expression of GLUT4 mRNA. 
SUMMARY 
The efficacy of chromium supplementation is somewhat disputed.  While many 
studies have shown that chromium improves glucose tolerance in certain populations, 
detractors have criticized these studies as being poorly controlled or not applicable to 
wide populations.  However, there has been significant data proving the benefits of 
chromium.  Even though these results cannot be applied to everyone, those populations 
with chromium deficiency or poor insulin response will in fact benefit from chromium 
supplementation. 
 One of the difficulties with evaluating chromium supplementation is the low level 
of absorption.  The body does not need high levels of chromium in order to function 
properly, therefore the absorption levels of chromium are very low.  Additionally, 
different forms of chromium are absorbed at different rates.  This combined with 
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differing levels of chromium in a self-selected diet make it difficult to properly evaluate 
the need and absorption rates of chromium supplementation. 
 Even though it has been shown that chromium increases glucose uptake, it has not 
been determined exactly how chromium does this.  Different animal studies have shown 
that chromium may increase insulin receptor tyrosine phosphorylation, increase Akt 
activation, increase the amount of GLUT4 near the plasma membrane or increase 
membrane fluidity.  The majority of studies have concluded that chromium increases 
glucose uptake only in the presence of insulin.  Therefore, it can be concluded that 
chromium works in conjunction with insulin to stimulate glucose uptake. 
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Expanded Methodology 
ANIMALS 
Twenty-eight male Sprague Dawley rats (Harlan, Houston, TX) were obtained for 
testing.  Rats were received at 7 weeks of age.  The rats were housed 2 to a cage and fed a 
standard laboratory chow (ProLab RMH 1800, Labdiet, Brentwood, MO) and provided 
with water ad libitum.  The room housing the animals was kept at 210 C with an artificial 
12 hour/12 hour light-dark cycle.  Upon arrival, rats were randomly separated by weight 
into 1 of 4 groups: chromium with sub maximal insulin (Cr-sIns, n=8), sub maximal 
insulin (sIns, n=9), chromium without insulin (Cr, n=6), and basal (Bas, n=5).  
EXPERIMENTAL DESIGN AND SURGERY 
In order to determine glucose uptake in the rat skeletal muscle, the hindlimb 
perfusion technique was utilized.  Hindlimb perfusion has been shown to be both a viable 
and popular experimental model to examine skeletal muscle glucose metabolism under 
physiological conditions (18, 71). 
Rats were subjected to testing at 9 weeks of age.  After a 12-hour fast, rats were 
anesthetized with an intraperitoneal injection of pentobarbital sodium (6.5 mg/100g body 
weight).  The surgical technique and the perfusion apparatus were similar to that 
previously described methods (37, 56).  The purpose of the surgery was to tie off vessels 
in the abdominal cavity and the left limb while exposing the inferior vena cava and 
descending aorta.  Cannulation of the right iliac artery and inferior vena cava could be 
performed, thus allowing the perfusate to flow from the arterial catheter, to the 
circulatory bed of the right hindlimb, and finally out through the venous catheter. 
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 Rats were placed on a heating pad in order to maintain normal body temperature 
throughout the surgery.  A ligature was tied around the tail before a midline abdominal 
incision was made through the skin.  The skin was reflected back and the superficial 
epigastric vessels were ligated.  Next, an incision was made through the abdominal wall 
from the pubic symphysis to the ziphoid process.  The stomach, spleen, pancreas and 
intestinal tract were removed from the cavity and wrapped in parafilm in order to increase 
access to the inferior vena cava and descending aorta.  The hypogastric arteries were 
ligated as well as the testicle and inferior mesenteric arteries.  The descending colon was 
ligated superior to the rectum and inferior to the xipohoid process then removed.  The 
trunk of the bladder was then ligated.  The iliolumbar arteries and veins, the right internal 
iliac artery and the right pubic-epigastric trunk were all ligated. 
 Next, loose ligatures were placed around the aorta and vena cava inferior to the 
renal vessels.  A second ligature was placed around the vena cava superior to the 
iliolumbar vessels.  A loose ligature was also placed around the left iliac artery. 
 The ligature around the descending aorta was tied and a small incision was made 
in the right iliac artery.  A polyethylene catheter was inserted into the incision to the tip 
of the femoral artery.  A 0.9% NaCl solution was then pushed through the catheter from a 
10 ml syringe.  The superior ligature around the inferior vena cava was tightened and the 
venous catheter was inserted and positioned below the distal ligature.  The distal ligature 
was then tied in order to secure the catheter.  Ten milliliters of 0.9% NaCl was pushed 
through the arterial catheter, flushing the right hindlimb.  After the catheters were in 
place, the rat was euthanized by an intracardiac injection of pentobarbital sodium. 
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HINDLIMB PERFUSION 
All solutions for the perfusion procedure were prepared in 6% BSA.  2 mM  
Na-pyruvate was added to the 6% BSA for the basal washout solution.  The Bas perfusate 
solution contained 2 mM Na-pyruvate, 6 mM glucose, 2 mM mannitol, 0.2 µCi/ml H3-2 
deoxyglucose and 0.15 µCi/ml C14-Sucrose.  The washout solution for the Cr group 
contained 2 mM Na-pyruvate and 0.096 µM CrCl3.  The Cr perfusate solution was 
composed of 2 mM Na-pyruvate, 0.096 µM CrCl3, 6 mM glucose, 2 mM mannitol, 0.2 
µCi/ml H3-2 deoxyglucose and 0.15 µCi/ml C14-Sucrose.  The washout solution for the 
sIns group was made of 2 mM Na-pyruvate and 200 µU/ml insulin.  The perfusate 
solution contained 2 mM Na-pyruvate, 200 µU/ml insulin, 6 mM glucose, 2 mM 
mannitol, 0.2 µCi/ml H3-2 deoxyglucose and 0.15 µCi/ml C14-Sucrose.  The Cr-sIns 
washout solution was made of 2 mM Na-pyruvate, 200 µU/ml insulin and 0.096 µM 
CrCl3.  The perfusate solution for the Cr-sIns group contained 2mM Na-pyruvate, 200 
µU/ml insulin, 0.096 µM CrCl3, 6 mM glucose, 2 mM mannitol, 0.2 µCi/ml H3-2 
deoxyglucose and 0.15 µCi/ml C14-Sucrose. 
 The cannulated rat was placed in line with the perfusion system.  The perfusate 
was continuously mixed on a magnetic stir plate.  The perfusate first passed through a 
roller pump, which was calibrated at 6 ml/min for the washout and 3 ml/min for the 
perfusate.  The perfusate then passed through approximately 3 meters of Silastic tubing 
(Dow Corning, Midland, MI) contained in an artificial lung, which was gassed with a 
mixture of 95% O2 and 5% CO2.  Next, the perfusate passed through a heated water 
jacket maintained at 370 C, and then through a bubble trap before entering the hindlimb of 
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the rat via the arterial catheter.  After circulating through the right hindlimb, the perfusate 
exited through the venous catheter and was collected in a beaker on ice for later analysis. 
 A manometer was placed in line after the bubble trap.  The pressure of the system 
ranged from 25 to 30 mmHg during the perfusion process.  The entire system was housed 
in a Plexiglas chamber, accessible from the front.  The rat was placed on a heating pad to 
maintain circulation.   
 The hindlimb was allowed to stabilize during a 10 minute washout period.  After 
the washout period, the rat was perfused for 25 minutes with the nonrecirculating 
perfusate solution.  Aliquots of the arterial samples were taken in order to determine the 
specific activity of the isotopes to help determine the skeletal muscle glucose uptake.  
After the perfusion was performed, the right gastrocnemius and quadriceps were 
removed, freeze clamped in liquid nitrogen and stored at -800C for later analysis. 
TISSUE PREPARATION FOR GLUCOSE UPTAKE 
Pieces of frozen gastrocnemius and quadriceps were cut and weighed.  The pieces 
were digested in 1ml of 1M KOH for 20 minutes at 60OC. The digested muscle was 
neutralized with 1ml of 1M HCL before 300µl of the mixture was added to 6 ml BioSafe 
II scintillation cocktail (Research Products International, Mt. Prospect, IL).  An LS-6500 
Multi Purpose Scintillation Counter (Beckman Coulter, Inc., Brea CA) was used to count 
duplicate samples of 3H and 14C.  Uptake of 2-DG in the muscle was calculated as the 
difference between total muscle 2-DG and extracellular 2-DG.  Extracellular space was 
determined from the from tissue concentration of [14C]-Sucrose, since the sucrose cannot 
cross the plasma membrane (34-36). 
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WESTERN BLOTTING 
Frozen gastrocnemious muscle was pulverized in a mortar and pestle in liquid 
nitrogen.  Homogenization buffer (20mM Hepes, 2mM EGTA, 50 mM NaF, 100mM 
KCl, 0.2 mM EDTA, 50 mM glycerophosphate, 1 mM DTT, 0.1 mM PMSF, 1mM 
Benzamidine, 0.5 mM Na Vanadate) was added to the chilled mortar.  After 
pulverization, the powdered muscle was added to a glass tissue grinder (Corning Stirrer 
Type RZR1, Wiarton, Ont. Canada) with additional homogenization buffer to dilute the 
sample at a dilution factor of 9:1.  The samples were thoroughly mixed in the grinder for 
10 seconds 3 times each.  The homogenate was then centrifuged at 40C for 10 minutes at 
14,000 x g.  Following the centrifugation, the protein concentration of the supernatant 
was analyzed using the Bradford method (19) (Bio-Rad Laboratories, Hercules, CA).  
The supernatant was then aliquoted into multiple vials and stored at -800 C until analyzed.   
When the Western analysis was performed, an aliquot was thawed and diluted 
with sample buffer (5ml 1.25M Tris, 10ml glycerol, 5ml 20%SDS, 2.25ml 
betamercaptoethanol, 1.6ml 0.25% Bromophenol Blue) at a 1:1 ratio followed by a 
denaturing of the sample for 7 minutes in water heated to 950C.  Duplicate samples 
containing 40 µg of protein were separated on 10% polyacrylamide gels by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE, Bio-Rad Laboratories, 
Richmond, CA) for 120 minutes at 160 V.  The proteins were then electrophoretically 
transferred at 85 V for 120 minutes from the polyacrylamide gels onto nitrocellulose 
membranes (Millipore, Corp., Bedford, MA) using a wet transfer unit (Bio-Rad 
Laboratories, Hercules, CA).  Membranes were cut at the 100 kDa marker, with the upper 
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portion probed for AS160 and the lower probed for Akt.  Membranes were blocked with 
a 7% solution of Tris-Tween bufferd saline (TTBS) and non-fat dry milk (NFDM) for 1 
hour.  Membranes were then washed 3 times for 5 minutes then incubated overnight with 
primary antibody diluted 1:800 in TTBS with 2% non-fat dry milk.  The antibodies used 
were specific for the proteins examined; phosphorylated AS160 (Thr642 #4288S), 
phosphorylated Akt(Thr308, #4056S), total AS160 (Anti-AS160 Rab-GAP Rabbit 
antiserum) and total Akt (Akt Rabbit Ab).  All antibodies were purchased from Cell 
Signaling Technology (Danvers, MA) except total AS160, which was purchased from 
Upstate (Temecula, CA). 
Following the overnight incubation, the membranes were washed with TTBS 3 
times for 5 minutes and then incubated for 90 minutes in secondary antibody (anti-rabbit, 
HRP-linked IgG, #7974, Cell Signaling Technology) that was diluted to 1:750 in 2% 
TTBS and NFDM for all proteins examined.  After further washing, the membranes were 
placed in enhanced chemiluminescence reagent (Perkins Elmer, Boston, MA) for two 
minutes.  A Molecular Imager Chemidoc XRS (Bio-Rad Laboratories, Hercules, CA) was 
used in order to visualize the proteins.  Quantity One Analysis Software (Bio-Rad 
Laboratories, Hercules, CA) was used to quantify the mean density of the bands.  After 
exposure of phosphorylated proteins, membranes were placed in a stripping buffer (pH 
6.7, 7.5 g Tris Base, 20 g SDS, 7 ml β-me) for one hour.  Membranes were then washed 2 
times for 5 minutes and then probed for total protein.  Akt and AS160 phosphorylation 
was analyzed as a percentage of total Akt and AS160. 
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Appendix A – Muscle Homogenization 
Homogenization Buffer for Western Immunoblotting (100 ml, pH 7.4):  
 
- 20 mM HEPES (H-3378)        0.4766 g   
- 2 mM EGTA (E-4378)        0.0761 g  
- 50 mM NaF (S-7920)       0.209 g  
- 100 mM KCl (P-217)        0.746 g  
- 0.2 mM EDTA (ED-255)        0.0074 g  
- 50 mM glycerophosphate (G-6521)      1.08 g  
- 1mM DTT (D-0632)       0.015 g  
- 0.1 mM PMSF (P-7626)       0.00174 g  
- 1mM Benzamidine (B-6506)      0.01566 g  
- 0.5 mM Sodium Vanadate (S-6508)      0.0092 g  
  
Homogenization:  
1. Frozen muscle was pulverized in a liquid nitrogen cooled mortar and pestle with 
homogenization buffer 
2. Homogenize muscle on ice (3 x 10 sec strokes) with glass tissue grinder pestle 
(Corning Life Sciences, Acton, MA) that is rotated by an electrically powered stirrer 
(Caframo Stirrer Type RZR1, Wiarton, Ont. Canada) at 3000 rpm  
3. Aliquot supernatants into 1.5 ml Eppendorf tubes (approximately 80 µl per tube), and 
store at - 80°C.  
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Appendix B – Krebs Buffer 
Preparation of Krebs-Henseleit Buffer (KHB):  
 
Prepare Stock 1 and 2:  
  
KHB Stock 1 (1 L)  
Chemical Concentration Amount (g) FW 
NaCl 1.16 M 67.79 58.44 
KCl 46 mM 3.429 74.56 
KH2PO4 11.6 mM 1.578 136.1 
NaHCO3 253.0 mM 21.25 84.01 
  
KHB Stock 2  (1 L)  
Chemical Concentration Amount (g) FW 
CaCl2.2H2O 25 mM 3.675 147 
MgSO4.7H2O 11.6 mM 2.859 246.48 
 
 
Prepare 1 L KHB for dissolving BSA 
 -Add 100 ml of Stock 1 KHB into 700 ml ddH2O 
 -Gas with 02/CO2 (95%/5%) for 45 min 
 -Add 100 ml of Stock 2 KHB 
 -Bring to 1L with ddH2O 
 
Prepare 6% BSA 
 -Add 90 g BSA on top of 390 ml of gassed KHB 
 -Stir until dissolved 
-Add dissolved BSA into a dialysis tube then clamp end of tube to prevent leaking 
-Place dialysis tube into a tank containing 15 L of KHB and stir for 48 hours 
-Check concentration with refractometer 
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-Filter twice though micropore paper using a vacuum pump 
-Using the refractomter bring the BSA concentration to 6% with gassed BSA 
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Appendix C – Wet Transfer Buffer 
Preparation of Wet Transfer Buffer 
 
 Wet transfer buffer (2 L) 
Chemical Concentration Amount  
Tris 25 mM 6.06 g 
Glycine 192 mM 28.8 g 
Methanol 20% 400 ml 
 
-Add Tris, Glycine and Methanol to 1 L of ddH2O 
-Bring to volume of 2 L with ddH2O 
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Appendix D – Protein Assay (Bradford) 
Bradford Protein Assay 
 
Standard Protocol 
1. Remove the 1x dye reagent from 40C storage and let it warm to ambient 
temperature.  Invert the 1x dye a few times before use. 
2. To generate a standard curve, use 2 mg/ml BSA.  For the diluent, use the same 
buffer as in the samples.  Protein solutions are performed in duplicate.  Prepare 
the standard curve as follows: 
 
Tube # Standard Volume 
(µL) 
Source of 
Standard 
Diluent Volume 
(µL) 
Final [Protein] 
(µg/ml) 
1 70 2 mg/ml stock 0 2,000 
2 75 2 mg/ml stock 25 1,500 
3 70 2 mg/ml stock 70 1,000 
4 35 Tube 2 35 750 
5 70 Tube 3 70 500 
6 70 Tube 5 70 20 
7 70 Tube 6 70 125 
8 (blank) 0 0 70 0 
 
3. To duplicate 12x75 mm glass assay tubes, add 20 µl of each standard and 
unknown sample solution.  Add 1 ml of 1x dye reagent to each tube and vortex. 
4. Incubate at room temperature for 30 min.  
5. Set the spectrophotometer to 595 nm.  Zero the instrument with the blank.  
Measure absorbance of the standards and unknown samples. 
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Appendix E – Individual Muscle Data 
 
Glucose uptake data   
Rat Treatment 
Quad Glucose Uptake 
(µmol/g/h) 
Gast Glucose Uptake 
(µmol/g/h) 
2 Cr-sIns 4.27 5.68 
4 Cr-sIns 6.09 8.10 
5 Cr-sIns 7.97 11.22 
8 Cr-sIns 5.51 6.29 
10 Cr-sIns 9.33 6.84 
12 Cr-sIns 9.42 5.13 
14 Cr-sIns 5.01 7.12 
27 Cr-sIns 5.79 4.51 
1 sIns 2.69 4.89 
3 sIns 3.56 5.44 
7 sIns 5.89 6.47 
9 sIns 6.85 5.04 
11 sIns 4.68 5.52 
13 sIns 5.00 6.09 
15 sIns 4.66 3.28 
30 sIns 3.41 3.98 
33 sIns 4.16 2.75 
18 Cr 1.75 1.63 
21 Cr 1.39 1.26 
22 Cr 1.09 0.99 
25 Cr 1.59 1.59 
29 Cr 0.91 1.79 
34 Cr 0.80 1.01 
17 Bas 1.46 2.59 
19 Bas 1.51 1.71 
20 Bas 0.97 2.22 
24 Bas 1.28 1.07 
32 Bas 1.58 1.03 
    
Western blotting data   
Rat Treatment p-Akt/t-Akt p-AS160/t-AS160 
2 Cr-sIns 36% 12% 
4 Cr-sIns 19% 56% 
5 Cr-sIns 29% 15% 
8 Cr-sIns 23% 45% 
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10 Cr-sIns 24% 46% 
12 Cr-sIns 18% 41% 
14 Cr-sIns 23% 38% 
27 Cr-sIns 15% 44% 
1 sIns 35% 14% 
3 sIns 19% 17% 
7 sIns 13% 54% 
9 sIns 25% 62% 
11 sIns 38% 57% 
13 sIns 34% 13% 
15 sIns 18% 14% 
30 sIns 6% 37% 
33 sIns 14% 59% 
18 Cr 2% 5% 
21 Cr 2% 21% 
22 Cr 1% 4% 
25 Cr 5% 20% 
29 Cr 5% 18% 
34 Cr 7% 15% 
17 Bas 2% 3% 
19 Bas 3% 12% 
20 Bas 2% 6% 
24 Bas 7% 18% 
32 Bas 5% 27% 
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